Central Pharmaceutical Joint Stock Company No3 (DP3) Q3 2025 earnings summary

Executive summary

• Net revenue for Q3/2025 reached VND 120.2 billion, up from VND 95.2 billion in Q3/2024, with year-to-date net revenue at VND 306.4 billion, a slight increase year-over-year.

• Net profit after tax for the first nine months was VND 79.0 billion, up from VND 71.1 billion in the same period last year.

• Gross profit margin improved, with gross profit for Q3/2025 at VND 81.8 billion versus VND 61.1 billion in Q3/2024.

Financial highlights

• Total assets as of 30/09/2025 were VND 692.1 billion, up from VND 607.8 billion at the start of the year.

• Equity increased to VND 533.4 billion from VND 518.9 billion at the beginning of the year.

• Cash and cash equivalents at period end were VND 3.2 billion, down from VND 13.7 billion at the start of the year.

• Net cash inflow from operating activities was VND 168.6 billion, while net cash outflow from investing and financing activities totaled VND 179.1 billion.

• Basic EPS for the nine months was VND 3,674, up from VND 3,306 year-over-year.

Outlook and guidance

• The company continues to focus on pharmaceutical production, trading, and expansion of commercial services, with ongoing investments in fixed assets and infrastructure.